{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:39:56Z","timestamp":1792755596954,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Elicio Therapeutics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"DOI":"10.1038\/s41591-026-04734-7","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:01:28Z","timestamp":1792753288000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9667-9833","authenticated-orcid":false,"given":"Ben","family":"George","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshabad","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2290-1884","authenticated-orcid":false,"given":"Craig E.","family":"Devoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Hosein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hendifar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer B.","family":"Valerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7721-1699","authenticated-orcid":false,"given":"Tanios","family":"Bekaii-Saab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0269-9615","authenticated-orcid":false,"given":"Dana B.","family":"Cardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3765-3318","authenticated-orcid":false,"given":"Manuel","family":"Hidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5169-7085","authenticated-orcid":false,"given":"Pashtoon M.","family":"Kasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis D.","family":"Leal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Pelster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin D.","family":"Weekes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2751-6122","authenticated-orcid":false,"given":"Mark H.","family":"O\u2019Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6249-9180","authenticated-orcid":false,"given":"Thomas J.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3367-367X","authenticated-orcid":false,"given":"Syed M.","family":"Kazmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Mizrahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0198-2064","authenticated-orcid":false,"given":"Martin","family":"Maiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thian","family":"Kheoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jino","family":"Xavier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia P.","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison H.","family":"Milaszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Cabana-Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa K.","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Welkowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"DeMuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8600-9548","authenticated-orcid":false,"given":"Christopher M.","family":"Haqq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9281-480X","authenticated-orcid":false,"given":"Shubham","family":"Pant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7142-1246","authenticated-orcid":false,"given":"Zev A.","family":"Wainberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8076-9199","authenticated-orcid":false,"given":"Eileen M.","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"4734_CR1","first-page":"e70043","volume":"76","author":"RL Siegel","year":"2026","unstructured":"Siegel, R. L., Kratzer, T. B., Wagle, N. S., Sung, H. & Jemal, A. Cancer statistics, 2026. CA Cancer J. Clin. 76, e70043 (2026).","journal-title":"CA Cancer J. Clin."},{"key":"4734_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-73525-y","volume":"10","author":"A Bengtsson","year":"2020","unstructured":"Bengtsson, A., Andersson, R. & Ansari, D. The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data. Sci. Rep. 10, 16425 (2020).","journal-title":"Sci. Rep."},{"key":"4734_CR3","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1245\/s10434-020-08235-w","volume":"27","author":"AEJ Latenstein","year":"2020","unstructured":"Latenstein, A. E. J. et al. Conditional survival after resection for pancreatic cancer: a population-based study and prediction model. Ann. Surg. Oncol. 27, 2516\u20132524 (2020).","journal-title":"Ann. Surg. Oncol."},{"key":"4734_CR4","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1038\/s41591-026-04537-w","volume":"32","author":"I Aronchik","year":"2026","unstructured":"Aronchik, I. et al. Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer. Nat. Med. 32, 2865\u20132877 (2026).","journal-title":"Nat. Med."},{"key":"4734_CR5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1056\/NEJMoa2605555","volume":"395","author":"EM O\u2019Reilly","year":"2026","unstructured":"O\u2019Reilly, E. M. et al. Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer. N. Engl. J. Med. 395, 325\u2013337 (2026).","journal-title":"N. Engl. J. Med."},{"key":"4734_CR6","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","volume":"375","author":"E Tran","year":"2016","unstructured":"Tran, E. et al. T-cell transfer therapy targeting mutant KRAS in cancer. N. Engl. J. Med. 375, 2255\u20132262 (2016).","journal-title":"N. Engl. J. Med."},{"key":"4734_CR7","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","volume":"386","author":"R Leidner","year":"2022","unstructured":"Leidner, R. et al. Neoantigen T-cell receptor gene therapy in pancreatic cancer. N. Engl. J. Med. 386, 2112\u20132119 (2022).","journal-title":"N. Engl. J. Med."},{"key":"4734_CR8","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1158\/1078-0432.CCR-21-0849","volume":"27","author":"N Levin","year":"2021","unstructured":"Levin, N. et al. Identification and validation of T-cell receptors targeting RAS hotspot mutations in human cancers for use in cell-based immunotherapy. Clin. Cancer Res. 27, 5084\u20135095 (2021).","journal-title":"Clin. Cancer Res."},{"key":"4734_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmeth.2025.101049","volume":"5","author":"BP Conn","year":"2025","unstructured":"Conn, B. P. et al. Generation of T cell responses against broad KRAS hotspot neoantigens for cell therapy or TCR discovery. Cell Rep. Methods 5, 101049 (2025).","journal-title":"Cell Rep. Methods"},{"key":"4734_CR10","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1038\/s41591-026-04361-2","volume":"32","author":"JB Haanen","year":"2026","unstructured":"Haanen, J. B., Schumacher, T. N. M., Kagan, J. C., Fritsch, E. F. & Wu, C. J. Publisher Correction: Clinical development of cancer vaccines. Nat. Med. 32, 1557\u20131557 (2026).","journal-title":"Nat. Med."},{"key":"4734_CR11","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1038\/s41591-025-03876-4","volume":"31","author":"ZA Wainberg","year":"2025","unstructured":"Wainberg, Z. A. et al. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results. Nat. Med. 31, 3648\u20133653 (2025).","journal-title":"Nat. Med."},{"key":"4734_CR12","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41591-023-02760-3","volume":"30","author":"S Pant","year":"2024","unstructured":"Pant, S. et al. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nat. Med. 30, 531\u2013542 (2024).","journal-title":"Nat. Med."},{"key":"4734_CR13","doi-asserted-by":"publisher","first-page":"5099","DOI":"10.1200\/JCO.2005.03.158","volume":"23","author":"DP Carbone","year":"2005","unstructured":"Carbone, D. P. et al. Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. J. Clin. Oncol. 23, 5099\u20135107 (2005).","journal-title":"J. Clin. Oncol."},{"key":"4734_CR14","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/s41416-020-0752-7","volume":"122","author":"DH Palmer","year":"2020","unstructured":"Palmer, D. H. et al. TG01\/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1\/2 trial. Br. J. Cancer 122, 971\u2013977 (2020).","journal-title":"Br. J. Cancer"},{"key":"4734_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-12-55","volume":"12","author":"OE Rahma","year":"2014","unstructured":"Rahma, O. E. et al. The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors. J. Transl. Med. 12, 55 (2014).","journal-title":"J. Transl. Med."},{"key":"4734_CR16","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/(SICI)1097-0215(19960208)65:4<450::AID-IJC10>3.0.CO;2-E","volume":"65","author":"MK Gjertsen","year":"1996","unstructured":"Gjertsen, M. K. et al. Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I\/II study. Int. J. Cancer 65, 450\u2013453 (1996).","journal-title":"Int. J. Cancer"},{"key":"4734_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-74711-8","volume":"17","author":"HH Wang","year":"2026","unstructured":"Wang, H. H. et al. Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial. Nat. Commun. 17, 7880 (2026).","journal-title":"Nat. Commun."},{"key":"4734_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-68324-4","volume":"17","author":"AL Huff","year":"2026","unstructured":"Huff, A. L. et al. Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. Nat. Commun. 17, 1538 (2026).","journal-title":"Nat. Commun."},{"key":"4734_CR19","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144\u2013150 (2023).","journal-title":"Nature"},{"key":"4734_CR20","doi-asserted-by":"publisher","unstructured":"Sethna, Z. et al. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Nature https:\/\/doi.org\/10.1038\/s41586-024-08508-4 (2025).","DOI":"10.1038\/s41586-024-08508-4"},{"key":"4734_CR21","doi-asserted-by":"publisher","unstructured":"Trevaskis, N. L., Kaminskas, L. M. & Porter, C. J. H. From sewer to saviour-targeting the lymphatic system to promote drug exposure and activity. Nat. Rev. Drug Discov. 14, 781\u2013803 https:\/\/doi.org\/10.1038\/nrd4608 (2015).","DOI":"10.1038\/nrd4608"},{"key":"4734_CR22","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nature12978","volume":"507","author":"H Liu","year":"2014","unstructured":"Liu, H. et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature 507, 519\u2013522 (2014).","journal-title":"Nature"},{"key":"4734_CR23","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1158\/2326-6066.CIR-17-0607","volume":"6","author":"KD Moynihan","year":"2018","unstructured":"Moynihan, K. D. et al. Enhancement of peptide vaccine immunogenicity by increasing lymphatic drainage and boosting serum stability. Cancer Immunol. Res. 6, 1025\u20131038 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"4734_CR24","doi-asserted-by":"publisher","first-page":"eabe5819","DOI":"10.1126\/sciadv.abe5819","volume":"7","author":"MP Steinbuck","year":"2021","unstructured":"Steinbuck, M. P. et al. A lymph node\u2013targeted amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2. Sci. Adv. 7, eabe5819 (2021).","journal-title":"Sci. Adv."},{"key":"4734_CR25","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2024.42.16_suppl.2636","volume":"42","author":"CE Devoe","year":"2024","unstructured":"Devoe, C. E. et al. AMPLIFY-7P, a first-in-human safety and efficacy trial of adjuvant mKRAS-specific lymph node targeted amphiphile ELI-002 7P vaccine in patients with minimal residual disease\u2013positive pancreatic and colorectal cancer. J. Clin. Oncol. 42, 2636 (2024).","journal-title":"J. Clin. Oncol."},{"key":"4734_CR26","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2022.3829","volume":"8","author":"T Conroy","year":"2022","unstructured":"Conroy, T. et al. Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer. JAMA Oncol. 8, 1571\u20131578 (2022).","journal-title":"JAMA Oncol."},{"key":"4734_CR27","doi-asserted-by":"publisher","unstructured":"Palmer, D. H. et al. Pancreatic adenocarcinoma: long-term outcomes of adjuvant therapy in the ESPAC4 phase III trial. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.24.01118 (2024).","DOI":"10.1200\/JCO.24.01118"},{"key":"4734_CR28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/COC.0000000000000633","volume":"43","author":"RA Abrams","year":"2020","unstructured":"Abrams, R. A. et al. Results of the NRG oncology\/RTOG 0848 adjuvant chemotherapy question\u2014erlotinib+gemcitabine for resected cancer of the pancreatic head. Am. J. Clin. Oncol. 43, 173\u2013179 (2020).","journal-title":"Am. J. Clin. Oncol."},{"key":"4734_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24562-2","volume":"12","author":"AS Bear","year":"2021","unstructured":"Bear, A. S. et al. Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting. Nat. Commun. 12, 4365 (2021).","journal-title":"Nat. Commun."},{"key":"4734_CR30","doi-asserted-by":"publisher","first-page":"12826","DOI":"10.1073\/pnas.1921964117","volume":"117","author":"MJW Sim","year":"2020","unstructured":"Sim, M. J. W. et al. High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D. Proc. Natl Acad. Sci. USA 117, 12826\u201312835 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4734_CR31","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1158\/2326-6066.CIR-15-0188","volume":"4","author":"QJ Wang","year":"2016","unstructured":"Wang, Q. J. et al. Identification of T-cell receptors targeting KRAS-mutated human tumors. Cancer Immunol. Res. 4, 204\u2013214 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"4734_CR32","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s00109-025-02585-2","volume":"103","author":"S Ebrahimi","year":"2025","unstructured":"Ebrahimi, S. et al. Targeting mutated KRAS by HLA-A*02:01 restricted anti-KRAS TCR-mimic CAR and bispecific T cell engager. J. Mol. Med. 103, 1231\u20131246 (2025).","journal-title":"J. Mol. Med."},{"key":"4734_CR33","doi-asserted-by":"publisher","first-page":"902709","DOI":"10.3389\/fimmu.2022.902709","volume":"13","author":"RB Baleeiro","year":"2022","unstructured":"Baleeiro, R. B. et al. Optimized anchor-modified peptides targeting mutated ras are promising candidates for immunotherapy. Front. Immunol. 13, 902709 (2022).","journal-title":"Front. Immunol."},{"key":"4734_CR34","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1093\/oncolo\/oyae155","volume":"29","author":"GP Botta","year":"2024","unstructured":"Botta, G. P. et al. Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma. Oncologist 29, 859\u2013869 (2024).","journal-title":"Oncologist"},{"key":"4734_CR35","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403, 632\u2013644 (2024).","journal-title":"Lancet"},{"key":"4734_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09974-7","volume":"22","author":"T Ma","year":"2022","unstructured":"Ma, T. et al. Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage II pancreatic cancer: a prospective, randomized, open-label, single center trial. BMC Cancer 22, 865 (2022).","journal-title":"BMC Cancer"},{"key":"4734_CR37","doi-asserted-by":"publisher","first-page":"102632","DOI":"10.1016\/j.tranon.2025.102632","volume":"63","author":"J Dardare","year":"2026","unstructured":"Dardare, J. et al. Radiotherapy in the management of PDAC, from past to present. Transl. Oncol. 63, 102632 (2026).","journal-title":"Transl. Oncol."},{"key":"4734_CR38","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.molmed.2017.08.007","volume":"23","author":"GP Linette","year":"2017","unstructured":"Linette, G. P. & Carreno, B. M. Neoantigen vaccines pass the immunogenicity test. Trends Mol. Med. 23, 869\u2013871 (2017).","journal-title":"Trends Mol. Med."},{"key":"4734_CR39","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","volume":"183","author":"PA Ott","year":"2020","unstructured":"Ott, P. A. et al. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell 183, 347\u2013362 (2020).","journal-title":"Cell"},{"key":"4734_CR40","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","volume":"18","author":"E Blass","year":"2021","unstructured":"Blass, E. & Ott, P. A. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat. Rev. Clin. Oncol. 18, 215\u2013229 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"4734_CR41","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","volume":"27","author":"Z Hu","year":"2021","unstructured":"Hu, Z. et al. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat. Med. 27, 515\u2013525 (2021).","journal-title":"Nat. Med."},{"key":"4734_CR42","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/nm.4200","volume":"22","author":"KD Moynihan","year":"2016","unstructured":"Moynihan, K. D. et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat. Med. 22, 1402\u20131410 (2016).","journal-title":"Nat. Med."},{"key":"4734_CR43","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1158\/2326-6066.CIR-22-0978","volume":"12","author":"DJ Drakes","year":"2024","unstructured":"Drakes, D. J. et al. Lymph node-targeted vaccine boosting of TCR T-cell therapy enhances antitumor function and eradicates solid tumors. Cancer Immunol. Res. 12, 214\u2013231 (2024).","journal-title":"Cancer Immunol. Res."},{"key":"4734_CR44","doi-asserted-by":"publisher","unstructured":"Ma, L. et al. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell https:\/\/doi.org\/10.1016\/j.cell.2023.06.002 (2023).","DOI":"10.1016\/j.cell.2023.06.002"},{"key":"4734_CR45","doi-asserted-by":"publisher","unstructured":"Haldar, S. D. et al. First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.CD-25-2245 (2026).","DOI":"10.1158\/2159-8290.CD-25-2245"},{"key":"4734_CR46","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1158\/1078-0432.CCR-25-0821","volume":"32","author":"BZ Stanger","year":"2026","unstructured":"Stanger, B. Z. & Vonderheide, R. H. KRAS inhibitors in pancreas cancer: facts and hopes about the immunotherapy we have all been waiting for. Clin. Cancer Res. 32, 1389\u20131396 (2026).","journal-title":"Clin. Cancer Res."},{"key":"4734_CR47","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ccell.2024.02.012","volume":"42","author":"M Molina-Arcas","year":"2024","unstructured":"Molina-Arcas, M. & Downward, J. Exploiting the therapeutic implications of KRAS inhibition on tumor immunity. Cancer Cell 42, 338\u2013357 (2024).","journal-title":"Cancer Cell"},{"key":"4734_CR48","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1158\/2159-8290.CD-24-1475","volume":"15","author":"M Orlen","year":"2025","unstructured":"Orlen, M. et al. T-cell dependency of tumor regressions and complete responses with RAS(ON) multi-selective inhibition in preclinical models of pancreatic ductal adenocarcinoma. Cancer Discov. 15, 1697\u20131716 (2025).","journal-title":"Cancer Discov."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04734-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04734-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04734-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:01:29Z","timestamp":1792753289000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04734-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":48,"alternative-id":["4734"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04734-7","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"10 September 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.G. reports personal fees from Ipsen, Foundation Medicine, Boston Scientific, Astellas Pharma and Amgen; grants and personal fees from Taiho Oncology, Roche\/Genentech, AstraZeneca and Pfizer; and grants from Hoffman La-Roche, Toray, Hutchison MediPharma, Mirati Therapeutics, CARsgen Therapeutics, GlycoNex, Helix Biopharma, Tvardi Therapeutics, Transcenta, BioNTech, Legend Biotech, Elicio Therapeutics and Obsidian. H.S. reports honoraria from UpToDate; consulting or advisory roles from Merck, Dewpoint Therapeutics and Zola Therapeutics; speakers\u2019 bureau with PeerDirect; research funding from Elicio Therapeutics, AstraZeneca and Daiichi Sankyo; and travel, accommodations and expenses from Dava Oncology. C.E.D. reports honoraria from Vivacitas; consultancy\/advisory board relationship with Pfizer; and research funding (to institution) from Elicio Therapeutics. V.C. has held consulting or advisory roles at Immuneering, Ispen, Gristone Oncology, Westwood Bioscience, Perthera and Apeiron Biologics. He has been on the speakers\u2019 bureau for Ipsen and Celgene. He has received research funding (to institution) from Elicio Therapeutics, Roche and Merck. A.H. is a consultant for Novartis, Ipsen, Valar Labs, PANCAN, Faraday Pharmaceuticals, Amgen, Regeneron, Exelexis, Alcresta Therapeutics, Pfizer, Curium Pharma and Merck; has received research funding from Ipsen; institutional research funding from NGM Biopharmaceuticals and Elicio Therapeutics; travel fees from Halozyme; and other compensation from RayzeBio. P.J.H. has held consulting or advisory roles at Fibrogen, Betaglue Therapeutics, Revolution Medicines, and Elicio Therapeutics (Scientific Advisory Board\/stock ownership). He has received research funding (to institution) from Elicio Therapeutics. D.W.K. reports grants or contracts from Bold Therapeutics, research funding (to institution) from Elicio Therapeutics, and payment or honoraria from AstraZeneca. J.B.V. reports research funding (to institution) from Elicio Therapeutics, and Honoraria from AstraZeneca. T.B.-S. reports research funding (to institution) from Elicio Therapeutics, Amgen, Ipsen, Lilly, Bayer, Roche\/Genentech, AbbVie, Incyte, Immuneering, Seagen, Pfizer, Boehringer Ingelheim, Janssen, Eisai, Daiichi Sankyo\/UCB Japan, AstraZeneca, Exact Sciences, Natera, Treos Bio, Celularity, Sobi, BeiGene, Foundation Medicine, Arcus Biosciences, Stemline Therapeutics, Kanaph Therapeutics, Deciphera, Illumina, Caladrius Biosciences and Zai Lab. Other relationships: Exelixis, Merck (Inst), AstraZeneca, Lilly, Pancreatic Cancer Action Network, FibroGen, Suzhou Kintor Pharmaceuticals, 1Globe Health Institute, Imugene, Xilis, Replimune, Sun Biopharma and UpToDate. D.B.C. reports consulting fees from Sago Pharma and the KOL Connection; grant and\/or research funding to institution from Elicio Therapeutics, Novartis, XBiotech, Elicio and Arcus Biosciences; and travel reimbursement from Arcus Biosciences. M.H. reports research funding (to institution) from Elicio Therapeutics; other support from Bristol-Myers Squibb and Nelum; personal fees and other support from Champions Oncology, InxMed and OncoMatrix; and personal fees from MiNKi and Peaches outside the submitted work, as well as being a member of the Bristol-Myers Squibb board of directors. P.M.K. reports consultancy\/advisory board relationships with Elicio (Scientific Advisory Board Member\/Stock Ownership), Founder, Percision BioSensors; consultancy\/advisory board relationships with Agenus, Astellas, AstraZeneca, Beixon, Elicio Therapeutics, Guardant Health, Illumina, Natera, Foundation Medicine, Daichi Sankyo, Tempus, Bayer, MSD Oncology\/Merck, Neogenomics, Delcath Systems, QED, Taiho Oncology (self\/institution), Exact Sciences, Eisai, BostonGene, Neogenomics, Saga Diagnostics, Regeneron, Servier, Seagen, Lilly, Xilio Therapeutics and Ipsen (to institution); and research funding\/trial support from Merck (to institution), Novartis (to institution), and Agenus Bio (to institution). A.D.L. reports honoraria from MedPro Specialty Advisory Board; institutional contracts with Elicio Therapeutics, Bristol-Myers Squibb, Exelixis, FameWave, Antengene, Arrys Therapeutics, Hutchison Medipharma, Corcept Therapeutics, Conjupro Biotherapeutics, Takeda, Boehringer Ingelheim Pharmaceuticals, Johnson & Johnson, AbbVie and Bayer U.S. for trials where she is the local principal investigator. She served as Pancreatic Cancer\/Neuroendocrine Co-Chair on the Elsevier ClinicalPath Oncology Committee during the course of this clinical trial. M.P. reports research funding (to institution) from Arcus Biosciences, Astellas Pharma, Codiak Biosciences, CytomX, Eisai, Elicio Therapeutics, Gritstone, HiberCell, Immune-Onc Therapeutics, OncXerna Therapeutics, SQZ Biotechnologies, Surface Oncology, TransThera Sciences and ZielBio. N.F. reports research funding (to institution) from Elicio Therapeutics. C.D.W. reports research funding from Elicio Therapeutics, Novartis, Actuate Therapeutics, Merck, AstraZeneca, Dicephera Pharmaceuticals, Genentech\/Roche and Mirati. Advisory board relationships with Ipsen, Celgene, Novartis, Merrimack, Actuate Therapeutics and Genentech. M.H.O. reports research funding (to institution) from Bristol-Myers Squibb, Celldex, Elicio, Revolution Medicine, Verastem, Genentech, Merck, Persevere, Parabalis, Jazz, Incyte, AstraZeneca and Arcus; grants and nonfinancial support from Stand Up To Cancer, Lustgarten Foundation; and advisory board fees from Natera, Revolution Medicine and Verastem. T.J.G. reports DSMB membership for Pfizer, Nihon Medi-Physics, KAHR Medical and Arbele; consultant\/advisory fees from Avammune Therapeutics, BillionToOne, Exact Sciences, Summit Therapeutics, Janssen Oncology, Pfizer and Genentech; research funding (to institution) from Bristol-Myers Squibb, Merck, AstraZeneca, Lilly, Bayer, Incyte, Ipsen, Genentech, Astellas Pharma, GlaxoSmithKline, Amgen, OncoC4, BillionToOne, Jounce Therapeutics, Elicio Therapeutics, AMAL Therapeutics\/Boehringer Ingelheim, Seagen, Regeneron and Deciphera. S.M.K. reports research funding (to institution) from Elicio Therapeutics and Johnson & Johnson. J.D.M. reports research funding (to institution) from Elicio Therapeutics; honoraria from Exelixis and AstraZeneca; consulting or advisory fees from Exelixis, Daichii Sankyo, Seagen and Amgen; and speakers\u2019 bureau participation from Exelixis, AstraZeneca and Bristol-Myers Squibb Foundation. S.N. reports research funding (to institution) from Bristol-Myers Squibb, Mirati Therapeutics, Strata Oncology, Elicio Therapeutics, Merck and Iovance. M.M. reports no conflicts of interest. T.K. reports consulting and stock ownership from Elicio Therapeutics. G.A. and J.X. report consulting from Elicio Therapeutics. J.P.S., M.H.M., X.C.-P., J.R.P., L.K.M., E.W., P.C.D. and C.M.H. are employees of Elicio Therapeutics and, as such, receive salary and benefits, including stock ownership. L.K.M., P.C.D. and C.M.H. have amphiphile vaccine patents pending: (patent number 12,138,301 (United Arab Emirates, Brazil, Canada, China, Hong Kong, India, Japan, South Korea, Mexico, Nigeria, Thailand, USA, South Africa) and patent number 12,247,052 (United Arab Emirates, Brazil, Canada, China, India, Japan, South Korea, Thailand, USA, South Africa)) to Elicio Therapeutics. S.P. reports research funding (to institution) from Amal Therapeutics, Arqule, Bristol-Myers Squibb, Eli Lilly, Elicio Therapeutics, Holy Stone Healthcare, Immuneering, ImmunoMET, Ipsen, Lilly, Mirati Therapeutics, Novartis, Purple Biotech, Rgenix, Sanofi-Aventis, Xencor, Astellas, Framewave, 4D Pharma, Boehringer Ingelheim, NGM Biopharmaceuticals, Janssen, Arcus Biosciences, Biontech, Zymeworks and Pfizer. Financial relationship consultant\/advisory fees from: Alligator Bioscience, Askgene Pharma, AstraZeneca, BPGBio, Zymeworks, Ipsen, Nihon Medi-Physics, Novartis, Janssen, Jazz Pharmaceuticals, US WorldMeds and Boehringer Ingelheim. Z.A.W. reports consultant\/advisory fees from Alligator Bioscience, Bayer, Lilly Oncology, AstraZeneca, Merck, Merck KGaA, Daiichi Sankyo, Macrogenics, Amgen, Bristol-Myers Squibb, Astellas, Ipsen, Arcus, Novartis, PureTech, Roche, Seagen and Pfizer; and received research funding (institutional) from Elicio Therapeutics, Five Prime Therapeutics, Arcus, Pfizer, Plexxikon, Novartis and Merck. E.M.O. reports Genentech\/Roche, BioNTech, Bristol-Myers Squibb, AstraZeneca, Arcus, Elicio Therapeutics, Helsinn Healthcare, Parker Institute, NIH\/NCI, Puma Biotechnology, Digestive Care, Break Through Cancer, Agenus, Amgen, Revolution Medicines, QED, Yiviva (research funding to institution), Abbvie, Arcus, AstraZeneca, Autem Medical, Ability Pharma, Alligator BioSciences, Agenus, Berry Genomics, BioNTech SE, Boehringer Ingelheim, Ipsen, Ikena, Merck, Moma Therapeutics, Novartis, Leap Therapeutics, Astellas, Bristol Meyers Squibb, Revolution Medicines, Regeneron, Tango (consulting\/DSMB), Thetis Pharma (uncompensated relationship), BioNTech, Arcus (travel) and AbbVie (spouse).","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}